Prostatic Neoplasms, Castration-Resistant
-
Subject Areas on Research
-
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
-
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
-
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
-
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
-
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
-
A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer.
-
ATM deficiency promotes progression of CRPC by enhancing Warburg effect.
-
Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy.
-
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
-
Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
-
Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
-
Aggressive variants of castration-resistant prostate cancer.
-
Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
-
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
-
Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics
-
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
-
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
-
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
-
Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.
-
Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply.
-
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
-
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
-
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
-
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
-
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.
-
Biomarkers in castration-resistant prostate cancer.
-
Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study.
-
Burden of disease matters when it comes to systemic therapy for prostate cancer.
-
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
-
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.
-
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
-
Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?
-
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
-
Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
-
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
-
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
-
Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer.
-
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
-
Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.
-
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
-
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
-
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
-
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.
-
Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
-
Clinical phenotypes of castration-resistant prostate cancer.
-
Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future.
-
Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.
-
Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
-
Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
-
Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.
-
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
-
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
-
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
-
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
-
DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.
-
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
-
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
-
Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy.
-
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
-
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
-
Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
-
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
-
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
-
Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
-
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
-
EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
-
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
-
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
-
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
-
Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.
-
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
-
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
-
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
-
Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
-
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
-
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
-
Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
-
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
-
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
-
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
-
Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
-
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
-
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
-
Hormone naïve prostate cancer: predicting and maximizing response intervals.
-
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
-
Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
-
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.
-
Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
-
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
-
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
-
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
-
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
-
Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
-
Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
-
Integrative clinical genomics of advanced prostate cancer.
-
Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
-
LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
-
Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46.
-
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.
-
Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
-
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
-
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
-
Making progress on progression in metastatic prostate cancer.
-
Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
-
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
-
Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.
-
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
-
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
-
Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells.
-
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
-
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
-
NUAK family kinase 2 is a novel therapeutic target for prostate cancer.
-
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.
-
New treatment options in castration-resistant prostate cancer.
-
New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?
-
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
-
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
-
Novel therapies are changing treatment paradigms in metastatic prostate cancer.
-
Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
-
Obesity, race, and long-term prostate cancer outcomes.
-
Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
-
Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
-
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
-
PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer.
-
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
-
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
-
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
-
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
-
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
-
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
-
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
-
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
-
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
-
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
-
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
-
Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.
-
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
-
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
-
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
-
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
-
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
-
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
-
Platinum sensitivity in metastatic prostate cancer: does histology matter?
-
Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.
-
Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
-
Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
-
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
-
Precision Medicine Approaches When Prostate Cancer Akts Up.
-
Preclinical and Coclinical Studies in Prostate Cancer.
-
Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH.
-
Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
-
Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.
-
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
-
Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.
-
Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
-
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
-
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
-
Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
-
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
-
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
-
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
-
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
-
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
-
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.
-
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
-
Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
-
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.
-
Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.
-
Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer.
-
Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency.
-
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
-
Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
-
Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
-
Racial Discrepancies in Overall Survival among Men Treated with 223Radium.
-
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
-
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
-
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
-
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.
-
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
-
Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
-
Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
-
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
-
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
-
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
-
Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.
-
Reply to M.A.N. Şendur et al and J. Michels.
-
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
-
Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.
-
SRRM4 gene expression correlates with neuroendocrine prostate cancer.
-
Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
-
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
-
Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.
-
Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
-
Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
-
Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
-
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
-
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
-
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
-
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
-
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).
-
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.
-
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
-
The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.
-
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
-
The role of AR-V7 testing in the management of metastatic CRPC.
-
The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer.
-
The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.
-
Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC.
-
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
-
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
-
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
-
Using circulating tumor cells to inform on prostate cancer biology and clinical utility.
-
Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.
-
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
-
Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
-
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.